Quick Links
Past Events

Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.


Not an official event of the 2017 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Clovis Oncology, Inc. and Myriad Genetics, Inc.

Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

Redefining Ovarian Cancer Treatment Paradigms by Maximizing Therapeutic Outcomes With PARP Inhibitors

Redefining Ovarian Cancer Treatment Paradigms by Maximizing Therapeutic Outcomes With PARP Inhibitors

June 2, 2017
7:00 PM - 9:00PM

Hilton Chicago
Salon Ballroom A 1 & 2, Lower Level
720 S. Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400


The treatment landscape for ovarian cancer has changed substantially with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitor therapy. It is important for clinicians who treat patients with ovarian cancer to have a solid understanding of the mechanistic rationale for the use of these medications in order to optimize their therapeutic application. Other challenges associated with maximizing therapeutic outcomes with potential PARP inhibitor use include selection of optimal testing strategies to personalize care, management of treatment toxicities, and development of evidence-based sequencing and combination strategies.

This case-based educational activity, featuring leading experts in the treatment of patients with ovarian cancer, has been developed to help clinicians with the management of these challenges. Multiple topics pertaining to the use of PARP inhibitors in the treatment of ovarian cancers and other tumor targets will be explored through a combination of didactic presentation and panel discussion. The program will conclude with a question-and-answer session to allow participants to interact with the faculty to discuss challenges seen in their own practice settings.

Target Audience

This educational program is directed toward all attendees of the 2017 ASCO Annual Meeting, including medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of ovarian cancers and other emerging tumor targets. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with ovarian cancers also will be invited to participate.

Learning Objectives

  • Describe how PARP inhibition strategies have been applied to the management of recurrent ovarian cancer
  • Discuss how care can be personalized via the use of testing strategies in BRCA-mutated and non‒BRCA-mutated patient populations with ovarian cancer
  • Examine PARP inhibitor mechanisms in the context of treatment resistance and emerging role in the maintenance setting
  • Describe effective strategies to proactively plan for and manage treatment-related toxicities in the setting of ovarian cancer

Program Chair

Robert L. Coleman, MD, FACOG, FACS
Professor, Vice Chair of Clinical Research
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Become a Member

Forgot Password?
Calendar of Events
Filter By